Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
Stuart Pocock(London School of Hygiene & Tropical Medicine), Robert N. Doughty(National Heart Foundation of New Zealand), Lars Køber(University of Copenhagen), Iain Squire(University of Leicester), Karl Swedberg(Brigham and Women's Hospital), Aldo P. Maggioni(Health Care Foundation), Gillian Whalley(University of Auckland), Katrina Poppe(University of Auckland), Cono Ariti(University of London), Joanna Dobson(University of London), John J.V. McMurray(University of Glasgow)
Cited by 1,323
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k